Aurisco Pharmaceutical (605116.SH) subsidiary receives drug registration certificate for Estradiol and Dydrogesterone Tablets

date
15:52 19/11/2026
avatar
GMT Eight
Aurisco Pharmaceutical (605116.SH) announced that recently, its wholly-owned subsidiary Yangzhou Aurisco Pharmaceutical Co., Ltd. received a Drug Registration Certificate for Estradiol and Dydrogesterone Tablets approved and issued by the National Medical Products Administration. The drug is a hormone replacement therapy (HRT) medication indicated for the treatment of estrogen deficiency symptoms in women who are at least 12 months postmenopausal.
Aurisco Pharmaceutical (605116.SH) announced that recently, its wholly-owned subsidiary Yangzhou Aurisco Pharmaceutical Co., Ltd. received a Drug Registration Certificate for Estradiol and Dydrogesterone Tablets approved and issued by the National Medical Products Administration. The drug is a hormone replacement therapy (HRT) medication indicated for the treatment of estrogen deficiency symptoms in women who are at least 12 months postmenopausal.